Drug Trial Radar · NCT02360579
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
Last checked: Nov 20, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
Sep 24, 2015
Primary completion
Oct 24, 2024
Study completion Oct 24, 2024
Sponsor
- Lead sponsor
- Iovance Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning regimen.
Conditions
- Metastatic Melanoma
Interventions
LifileucelBiological
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with lifileucel followed by IL-2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Assessment for Objective Response RateTime frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months
Locations
57 sites in 8 countries. Site status is shown where the registry gives one.
University of California San Diego Moores Cancer Center
La Jolla, California
The Angeles Clinic and Research Institute
Los Angeles, California
University of California Los Angeles - David Geffen School of Medicine - Westwood Rheumatology
Los Angeles, California
California Pacific Medical Center
San Francisco, California
University of Colorado Cancer Center
Aurora, Colorado
Yale Cancer Center
New Haven, Connecticut
University of Miami
Miami, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
University of Florida Health Cancer Center
Orlando, Florida
University of South Florida H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Indiana University
Indianapolis, Indiana
James Graham Brown Cancer Center
Louisville, Kentucky
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota
Atlantic Health System
Morristown, New Jersey
Rutgers University
New Brunswick, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
New York University Langone Medical Center
New York, New York
Providence Cancer Center Oncology and Hematology Care Clinic
Portland, Oregon
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, Pennsylvania
Virginia Commonwealth University
Richmond, Virginia
Seattle Cancer Care Alliance
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Centre Léon Bérard
Lyon, Auvergne-Rhône-Alpes, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, Auvergne-Rhône-Alpes, France
Gustave Roussy Cancer Campus
Villejuif, Île-de-France Region, France
Hôpital Dupuytren
Limoges, Limousin, France
Universitätsklinikum Würzburg
Würzburg, Germany
Universitaetsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
Universitaetsklinikum Tuebingen (UKT) - Suedwestdeutschen Tumorzentrum - Zentrum für Neuroonkologie
Tübingen, Baden-Wurttemberg, Germany
Universitätsklinikum Erlangen
Erlangen, Bavaria, Germany
Klinikum Rechts der Isar der Technischen Universität München
München, Bavaria, Germany
Universitätsklinikum Carl Gustav Carus
Dresden, Saxony, Germany
Universitätsklinikum Leipzig
Leipzig, Saxony, Germany
Universitätsklinikum Halle
Halle, Saxony-Anhalt, Germany
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Lübeck, Schleswig-Holstein, Germany
Szegedi Tudomanyegyetem Szent-Györgyi Albert Klinikai Központ
Szeged, Csongrád megye, Hungary
Istituto Europeo di Oncologia
Milan, Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Naples, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Forli-cesena, Italy
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.